USPTO 2015–2025 USPTO PatentsView US Corporation

Ionis Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 271 granted patents across 15 technology areas, active 2016–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

271

Total patents granted

CPC technology areas

22.9

Avg claims per patent

+22%

5-year filing velocity

The verdict

Ionis holds 271 US patents across 15 technology areas, rank #1,536 of 50,000 tracked assignees.

#1,536
of 50,000 US assignees by volume: Top 10%
by Innovation Score (52.2/100): 22.9
avg claims per patent: +22%
filing velocity, last 5 yrs

Portfolio overview

Ionis Pharmaceuticals, Inc. has been granted 271 US utility patents between 2016 and 2025, placing Ionis Pharmaceuticals, Inc. at rank #1,536 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.9 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Ionis Pharmaceuticals, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Ionis sits between China University Of Mining And Technology (272 patents, rank #1,532) and Garmin Switzerland Gmbh (270 patents, rank #1,540) - the closest US assignees by grant volume. The composite Innovation Score of 52.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 149 grants, compared with 122 in the 2015–2019 window, a +22% shift in five-year velocity. Steady filing volume suggests sustained innovation without dramatic pivots. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Ionis Pharmaceuticals, Inc.'s 22.9 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Ionis Pharmaceuticals, Inc. against peers pursuing similar technology classes.

China University…

272
Woodward

272
Central Glass

271
Fairchild Semicon…

271
Resonac

271
Techtronic Cordle…

271
Ionis Pharmaceuti… ◀

271
Colorado State Un…

270
Garmin Switzerland

270

What this shows Ionis holds 271 patents at rank #1,536, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Ionis

By rank, the assignees closest to #1,536 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Ionis's primary technology class.

Ionis's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

52 Top 10% higher than 90% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Ionis Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	20	7.4%
2017	42	15.5%
2018	27	10.0%
2019	33	12.2%
2020	32	11.8%
2021	28	10.3%
2022	33	12.2%
2023	25	9.2%
2024	17	6.3%
2025	14	5.2%

Which technologies does Ionis Pharmaceuticals, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 254

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 160

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 140

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 84

C12Y - ENZYMES 58

C07K - PEPTIDES 16

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 9

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 4

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 4

A61J - CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE 3

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 3

C07D - HETEROCYCLIC COMPOUNDS 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 1

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 1

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 1

Top 15 of 15 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Complex

Velocity Growing

Where it ranks

Overall rank by patents

#1,536

Across all tracked assignees

Innovation Score

52.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Ionis Pharmaceuticals, Inc. hold?

Ionis Pharmaceuticals, Inc. holds 271 US granted patents filed between 2016 and 2025, spanning 15 technology areas.

What is Ionis Pharmaceuticals, Inc.'s Innovation Score?

Ionis Pharmaceuticals, Inc. has an Innovation Score of 52.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Ionis Pharmaceuticals, Inc. focus on?

Ionis Pharmaceuticals, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 254 patents. The company has filed patents in 15 CPC subclasses total.

Is Ionis Pharmaceuticals, Inc.'s patent filing rate increasing or decreasing?

Ionis Pharmaceuticals, Inc.'s recent filing velocity is +22% compared to the prior five-year period. The company is maintaining or growing its patent output.

What does claim depth mean for Ionis Pharmaceuticals, Inc.'s patents?

Ionis Pharmaceuticals, Inc.'s patents average 22.9 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.

How is the Ionis Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Ionis's 271 grants land it in the top 10% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Ionis ranks #1,536 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.